Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

horse anti-thymocyte globulin

A purified, concentrated and sterile solution of horse-derived gamma globulin obtained by the immunization of horses with human T lymphocytes, with T-cell depleting and immunosuppressive activities. Upon administration, horse anti-thymocyte globulin (hATG) specifically recognizes, modulates and destroys T lymphocytes. Although the exact mechanism of action by which hATG causes immunosuppression is not completely understood, it is likely caused by a combination of T-lymphocyte depletion, reduction in T-cell activation and modulation of their cytotoxic activities. Administering of hATG prior to transplantation may reduce the risk of graft-versus-host disease (GvHD).
Synonym:anti-thymocyte globulin equine
antithymocyte globulin equine
ATG equine
equine ATG
horse ATG
lymphocyte immune globulin, anti-thymocyte globulin equine
US brand name:Atgam
Abbreviation:eATG
hATG
Search NCI's Drug Dictionary